Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity InvestmentFriday, July 3, 2009
NEW BRUNSWICK, N.J. and DUBLIN -- Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced a definitive agreement whereby Johnson...
Biogen Idec & Acorda Therapeutics Announce Collaboration Agreement to Develop & Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.Friday, July 3, 2009
CAMBRIDGE, MA and HAWTHORNE, NY – Biogen Idec (NASDAQ: BIIB) and Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that they have entered into...
Morphotek(R), Inc. Announces a Collaboration Agreement with Synageva BioPharma Corporation to Develop Treatments for Cancer & Infectious DiseaseThursday, July 2, 2009
EXTON, Penn. -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma...
New Drug That Could Dramatically Speed Up The Elimination Of River Blindness Across Africa Begins Clinical TrialThursday, July 2, 2009
A clinical trial is being launched in three African countries of a drug that could eliminate onchocerciasis, or river blindness, one of the leading infectious...
Human Genome Sciences to Host Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) in Systemic Lupus ErythematosusThursday, July 2, 2009
ROCKVILLE, Maryland -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it expects to have top-line results available on Monday, July 20, from...
New e-science service could accelerate cancer researchThursday, July 2, 2009
The University of Manchester and the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) have launched a major new e-science...
Research network wins approximately 5.7 million to target human and animal diseases in AfricaThursday, July 2, 2009
Deadly diseases including plague, Ebola and Rift Valley Fever are being targeted as part of a new multi-million pound international partnership involving African...
Santhera's FJORD phase IIb study demonstrates efficacy of JP-1730/Fipamezole for the treatment of dyskinesia in Parkinson's diseaseThursday, July 2, 2009
LIESTAL, Switzerland - Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today positive...
Study identifies biomarker that safely monitors tumor response to new brain cancer treatmentWednesday, July 1, 2009
LOS ANGELES -- A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response...
Parents to be offered test to detect inherited diseases in embryosWednesday, July 1, 2009
A universal genetic test for embryos that can screen for almost any inherited disease is to be offered to prospective parents within months, after research...
